Contributors: EpiConcept Paris; Direction des maladies infectieuses - Infectious Diseases Division Saint-Maurice; Santé publique France - French National Public Health Agency Saint-Maurice, France; IRCCS Ospedale Pediatrico Bambino Gesù = Bambino Gesù Children’s Hospital; Public Health Agency of Catalonia Barcelona, Spain (PHAC); Temple Street Children's University Hospital Dublin; National Institute of Public Health Prague; Instituto de Investigación Sanitaria de Navarra Pamplona, Spain (IdiSNA); Norwegian Institute of Public Health Oslo (NIPH); Biodiversité et Epidémiologie des Bactéries pathogènes - Biodiversity and Epidemiology of Bacterial Pathogens; Institut Pasteur Paris (IP); Our Lady's Children's Hospital Crumlin (OLCHC); Complejo Hospitalario de Navarra; Institut de Recerca Pediàtrica Hospital Sant Joan de Déu Barcelona, Spain; Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP); Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU); Universitat Internacional de Catalunya Barcelona (UIC); Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública = Consortium for Biomedical Research of Epidemiology and Public Health (CIBERESP); European Centre for Disease Prevention and Control Stockholm, Sweden (ECDC); The European Centre for Disease Prevention and Control (ECDC) funded the PERTINENT study (Framework contract n° ECDC/2015/017).; PERTINENT group : Epiconcept, France: Lore Merdrignac, Epiconcept; Camelia Savulescu, Epiconcept; Marta Valenciano, Epiconcept; Alain Moren, Epiconcept. Czech Republic: Pavla Křížová, National Institute of Public Health, Prague; Kateřina Fabiánová, National Institute of Public Health, Prague; Jana Zavadilová, National Institute of Public Health, Prague; Zuzana Blechová, University Hospital Na Bulovce, Prague; Květa Bláhová, University Hospital Motol, Prague; Pavel Kosina, University Hospital, Hradec Králové; Josef Sýkora, University Hospital, Pilsen; Alena Holčíková, University Hospital, Brno; Petr Širůček, University Hospital, Ostrava. France: Daniel Lévy-Brühl, Santé Publique France, Saint-Maurice; Fatima Aït El Belghiti, Santé Publique France, Saint-Maurice; Adèle Grembombo, Santé Publique France, Saint-Maurice; Sophie Guillot, Institut Pasteur, Paris; Sylvain Brisse, Institut Pasteur, Paris; Julie Toubiana, Institut Pasteur, Paris. Ireland: Suzanne Cotter, HSE-Health Protection Surveillance Centre, Dublin; Jane Murphy, Temple Street Children’s University Hospital, Dublin; Robert Cunney, Temple Street Children’s University Hospital, Dublin; Norma O’Shaughnessy, Temple Street Children’s University Hospital, Dublin; Adele Habington, Our Lady’s Children’s hospital Crumlin, Dublin; Niamh O’Sullivan, Our Lady’s Children’s hospital Crumlin, Dublin. Italy: Elisabetta Pandolfi, Bambino Gesù Children Hospital, Rome; Alberto E Tozzi, Bambino Gesù Children Hospital, Rome; Caterina Rizzo, Bambino Gesù Children Hospital, Rome; Luisa Russo, Bambino Gesù Children Hospital, Rome; Ilaria Campagna, Bambino Gesù Children Hospital, Rome; Francesco Gesualdo, Bambino Gesù Children Hospital, Rome; Sara Ciampini, Bambino Gesù Children Hospital, Rome; Valentina Annarosa Ferro, Bambino Gesù Children Hospital, Rome; Elena Boccuzzi, Bambino Gesù Children Hospital, Rome. Norway: Elmira Flem, Norwegian Institute of Public Health, Oslo; Håkon Bøås, Norwegian Institute of Public Health, Oslo; Terese Bekkevold, Norwegian Institute of Public Health, Oslo; Liliana Vazquez Fernandez, Norwegian Institute of Public Health, Oslo. Catalonia, Spain: Carmen Muñoz-Almagro, Instituto de Recerca Pediatrica Hospital Sant Joan de Deu, Barcelona; Universitat Internacional de Catalunya and CIBER of Epidemiology and Public Health CIBERESP; Cristina Esteva, Instituto de Recerca Pediatrica Hospital Sant Joan de Deu, Barcelona; CIBER of Epidemiology and Public Health CIBERESP; Miguel Lanaspa Perez, Instituto de Recerca Pediatrica Hospital Sant Joan de Deu, Barcelona; Mireia Jané, Public Health Agency of Catalonia, Barcelona; University of Barcelona; Gloria Carmona, Public Health Agency of Catalonia, Barcelona; Lesly Acosta, Universitat Politècnica de Catalunya - BarcelonaTech (UPC), Public Health Agency of Catalonia, Barcelona; Yolanda Jordan Garcia, Instituto de Recerca Pediatrica Hospital Sant Joan de Deu, Barcelona; CIBER of Epidemiology and Public Health CIBERESP. Navarra, Spain: Manuel García Cenoz, Instituto de Salud Pública de Navarra, IdiSNA – Navarre Institute for Health Research, Pamplona; Ana Navascués, Complejo Hospitalario de Navarra, Pamplona; Leticia Fernandino Zubieta, Instituto de Salud Pública de Navarra, IdiSNA – Navarre Institute for Health Research, Pamplona; Jesús Castilla, Instituto de Salud Pública de Navarra, IdiSNA - Navarre Institute for Health Research, Pamplona. Sentinelles, France: Thomas Hanslik, Sorbonne Université, INSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique (IPLESP UMRS 1136), Paris. ECDC: Sabrina Bacci, European Centre for Disease Prevention and Control, Stockholm, Sweden; Gianfranco Spiteri, European Centre for Disease Prevention and Control, Stockholm, Sweden.
نبذة مختصرة : International audience ; IntroductionPERTINENT is a pilot active surveillance system of infants hospitalised with pertussis in six European Union/European Economic Area countries (37 hospitals, seven sites).AimThis observational study aimed to estimate annual pertussis incidence per site from 2016 to 2018 and respective trends between 2017 and 2018. Pertussis cases were described, including their severity.MethodsWe developed a generic protocol and laboratory guidelines to harmonise practices across sites. Cases were hospitalised infants testing positive for Bordetella pertussis by PCR or culture. Sites collected demographic, clinical, laboratory data, vaccination status, and risk/protective factors. We estimated sites' annual incidences by dividing case numbers by the catchment populations.ResultsFrom December 2015 to December 2018, we identified 469 cases (247 males; 53%). The median age, birthweight and gestational age were 2.5 months (range: 0-11.6; interquartile range (IQR): 2.5), 3,280 g (range: 700-4,925; IQR: 720) and 39 weeks (range: 25-42; IQR: 2), respectively. Thirty cases (6%) had atypical presentation either with cough or cyanosis only or with absence of pertussis-like symptoms. Of 330 cases with information, 83 (25%) were admitted to intensive care units including five deceased infants too young to be vaccinated. Incidence rate ratios between 2018 and 2017 were 1.43 in Czech Republic (p = 0.468), 0.25 in Catalonia (p = 0.002), 0.71 in France (p = 0.034), 0.14 in Ireland (p = 0.002), 0.63 in Italy (p = 0.053), 0.21 in Navarra (p = 0.148) and zero in Norway.ConclusionsIncidence appeared to decrease between 2017 and 2018 in all but one site. Enhanced surveillance of hospitalised pertussis in Europe is essential to monitor pertussis epidemiology and disease burden.
Processing Request
No Comments.